This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Clinical Trials Market

Market Insights on Clinical Trials covering sales outlook, demand forecast & up-to-date key trends

Clinical Trials Market By Area (Oncology, Infectious Disease, Metabolic Disorders), Phase (Phase 0, Phase IV), Sponsor (Industry-sponsored, Government / Public, Non-governmental Organizations) & Region Forecast to 2019 - 2029

Clinical Trials Market Outlook

[179 Pages Report] Global Clinical Trials Market spending was valued at US$ 95 billion in 2019, and is expected to record a 4% compound annual growth rate (CAGR) through 2029.

Attributes

Details

Estimated Market Size (2019)

US$ 95 Bn

Global Spending on Clinical Trials by Europe and North America (2018)

80%

CAGR (2019-2029)

4%

Due to well-established clinical infrastructure and the preference of trial sponsors and collaborators to conduct the Clinical Trials Market in countries with a robust regulatory landscape, Europe and North America accounted for 80% of worldwide spending on Clinical Trials in 2018.

Except for China, where the number of clinical trials for cardiovascular indications outpaced those in the United States in 2018, the country is one of the most popular destinations for clinical trials across various therapy areas.

Customize this Report

Let us know your requirement to get
100% FREE customization

Key Factors Shaping the Clinical Trials Market Landscape

Spending on Oncology Drugs Remains High, Despite Complexities

Clinical trials for various oncology indications accounted for approximately 30% of all trials registered, also representing the therapeutic indication with the most number of drug launches. Most of the top industry sponsors of clinical trials allocated a significant proportion of their R&D expenditure to the oncology drug portfolio.

Among various oncology indications, non-small cell lung cancer (NSCLC) and breast cancer were predominantly targeted for clinical development. However, clinical trials market for oncology are steadily becoming more complex in terms of patient recruitment, clinical trial design parameters such as endpoints, narrower eligibility criteria, among others.

Growing Focus on Enhancing Clinical Trial Design Using Predictive Analytics

Clinical Trials Market Download Report Brochure

Predictive analytics tools including artificial intelligence and machine learning are already being used in several companies to develop models and guide decisions. Considering the plethora of health data currently available to clinical trial investigators, predictive analytics tools can be effectively leveraged in clinical trial design to identify patient characteristics that are more likely to respond to a specific treatment pattern, thereby increasing the success rates and reducing risk to large, multi-center clinical trials.

It can also aid in the development of precision approaches by assessing the effect of a certain therapeutic approach on a subset of patient population based on certain biomarkers. The potential for predictive analytics to influence clinical trial design is likely to hinge on the understanding of complex disease models by clinical trial investigators, and collaborative efforts are still underway to unlock the maximum impact on clinical development.

Developing Countries Offer Unprecedented Value to Clinical Trial Sponsors

Despite a third of all clinical trials market registered are located in the U.S., clinical trial sponsors have been offshoring clinical trials market to countries such as China, India, Russia, and Brazil for the past few years. These countries are attractive for several reasons: a large patient pool, well-developed healthcare infrastructure in urban areas, an abundance of skilled clinical staff for monitoring clinical trials, among other factors.

Governments in certain countries are also offering incentives for clinical trial sponsors to carry out clinical trials in these countries, which typically tend to be shorter and thus, also cost-effective. There have also been several ethical questions raised pertaining to clinical trials in developing countries, which put a damper on offshoring clinical trials.

Clinical Trials Landscape: Stakeholder Assessment

  • A significant proportion of clinical trials were initiated by large pharmaceutical companies, with Bristol-Myers Squibb, AstraZeneca, Merck & Co., Roche, and Johnson & Johnson rounding out the top 5 in terms of the number of trials.
  • Emerging pharmaceutical and biotechnology companies are continuing to exert their influence on the clinical trials sector, with a robust pipeline of therapeutic agents paving the way.
  • Companies such as Bristol-Myers Squibb, Merck & Co., Amgen, and some others focused their efforts on clinical trials for currently approved drugs to obtain marketing expansion, while companies such as AstraZeneca, GlaxoSmithKline, Johnson & Johnson, among others have a greater focus on drugs with no prior marketing authorization.
  • While assessing the therapeutic area focus, most companies heavily depended on oncology, where the number of clinical trials initiated was disproportionately large compared to the rest of their respective portfolios. Only a limited number of companies had a diverse allocation of therapeutic focus.
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

‘Clinical Trials’ Metamorphosing into a Connected, Streamlined Landscape

Complexities and data volumes in clinical trials are on a ceaseless rise. There is an urging need for pharma companies to increase R&D efforts, as development costs break records and patent cliffs approach. Integration of cloud and analytics is pervasively evident, and digital transformation in healthcare are making holistic changes in the clinical trial process.

The healthcare models are undergoing tectonic shifts and seeing massive inflow of new clinical trial models, which are organized, streamlined, and nurture patient engagement. Pharmaceutical companies are pushing the limits of R&D efforts to improvise their clinical trial models, which will help them cope up with ever-increasing developmental costs.

The New-Age Clinical Trials Are ‘Web’ Based

Biopharmaceutical companies are focused on implementing digital health in the clinical trials and operations. It is highly likely that pilot projects and investments to validate digital measures will continue to rise, abreast the uptake of patient centricity to empower convenient and personalized approaches.

The initial years of the ‘digitalization era’ also left some major imprints on the clinical trials landscape. Pzifer has already started focusing on new launches of web-based clinical trial outreach platforms, and other companies followed suit. Such efforts mark a new milestone for the global clinical trials space and fine tune the way clinical trials were conducted.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

North America and Europe – The Goldilocks Zone

North America and Europe present a favorable and standardized ecosystem for the clinical trials landscape – collectively estimated to create an opportunity worth ~ US$ 76 Bn in 2019. These regions often gain the first mover advantage in almost every technological disruption in light of their economic vigor; and in case of clinical trials, pharmaceutical giants are adopting artificial intelligence to disrupt all stages of the process – from linking eligible patients to respective studies, to monitoring data collection and adherence.

The Broader Perspective

The clinical trials landscape is witnessing a revolutionary phase, where new sources of data are being generated and put in the hands of patients. Pharma and medical device companies are emphasizing to bridge the gap between current scope of patient access at present and future, to help them maintain a healthy lifestyle.

As today’s clinical trials are way more sophisticated than the previous ones, the clinical trials landscape has been spectating persistent reformations to ensure that the essential supplies of patient kits are in right place at right time. High focus is also being placed on adaptive trial designs, which eases mid-study modifications based on accumulated data.

How Growth Will Unfold?

Faster clinical trials are crucial for pharma and medical device companies, as these are time- and capital-intensive. Spending on phase III clinical trials remains comparatively higher than phase II and phase I trials, owing to their greater complexity and need for larger patient pool.

Sponsors are highly likely to see greater room for success in developing regions, such as South Asia and East Asia. Moreover, the conduction of clinical trials across this fast-growing regions promises a new shade of advantages, including tax incentives and efficient regulatory pathways.

Key Segment

By Area:

  • Oncology
  • Infectious Disease
  • Metabolic Disorders
  • Cardiovascular
  • Neuroscience
  • Respiratory
  • Others

By Phase:

  • Phase 0
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Sponsor:

  • Industry-sponsored
  • Government / Public
  • Non-governmental Organizations
  • Others (Academic Medical Centers, Individuals, etc.)

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

The clinical trials market was valued at US$ 95 Bn by 2019, and is advancing at a CAGR of 4%.

Chiltern, Omnicare, PPD, Parexel, Kendle, and Quintles, are some of the leading companies in the clinical trials market.

Table of Content

1. Executive Summary

    1.1. Global Industry Outlook

    1.2. Industry Trends

    1.3. Analysis and Recommendations

2. Market Overview

    2.1. Sector Coverage / Taxonomy

    2.2. Definition / Scope / Limitations

    2.3. Key Phases in Clinical Trials

    2.4. Clinical Trials for Pharmaceutical Products v/s Medical Devices

3. Key Market Trends

    3.1. Key Trends Impacting the Sector

    3.2. Regulatory Trends

4. Key Success Factors

5. Global Clinical Trials Landscape and Analysis 2014-2018 and Outlook, 2019-2029

    5.1. Historical Number of Trials, 2009-2019, by Disease Area and Region

    5.2. Analysis of Clinical Trials by Sponsor, 2009-2019

    5.3. Analysis of Clinical Trials by Phase, 2009-2019

    5.4. Current and Future Trial Projections, 2019-2029

6. Global Clinical Trials Landscape – Economic Impact and Trial Cost Structure Analysis

    6.1. Regional Average Per-Patient Clinical Trial Costs

    6.2. Cost Components of Clinical Trials

    6.3. Economic Impact Analysis of Clinical Trials

        6.3.1. Direct Impact

        6.3.2. Indirect and Induced Impact

7. Global Clinical Trials Spending (in US$ Mn) Analysis 2014-2018 and Outlook, 2019-2029

    7.1. Historical Spending (US$ Mn) Analysis, 2014-2018

    7.2. Current and Future Spending (US$ Mn) Projections, 2019-2029

    7.3. % of Overall R&D Expenditure Attributable to Clinical Trials

8. Market Background & Context

    8.1. Essential Fundamentals of Clinical Trials

    8.2. Trial Design Considerations

    8.3. Impact of Digitization on Clinical Trials

    8.4. Macro-Economic Indicators

        8.4.1. Global GDP Growth Outlook

        8.4.2. R&D Investment as a % of GDP

        8.4.3. Number of Researchers

        8.4.4. Number of Hospitals & Hospital Beds

        8.4.5. Number of Diagnostic Labs

    8.5. Forecast Factors - Relevance & Impact

    8.6. Key Stakeholders in Clinical Trials & Interplay

        8.6.1. Public Sector Institutions

        8.6.2. Private Institutions / Individuals

        8.6.3. Drug & Device Manufacturers

        8.6.4. Contract Research Organizations

        8.6.5. Institutional Review Boards

        8.6.6. IT Infrastructure Providers 

        8.6.7. Hospitals & Healthcare Facilities

        8.6.8. Others 

    8.7. Industry Dynamics

        8.7.1. Drivers

        8.7.2. Challenges

        8.7.3. Opportunities

9. Global Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029, By Sponsor 

    9.1. Introduction / Key Findings

    9.2. Historical Number of Trials and Expenditure (US$ Mn) By Sponsor, 2014-2018

    9.3. Current and Future Number of Trials and Expenditure (US$ Mn) and Forecast By Sponsor, 2019 - 2029

        9.3.1. Industry-sponsored

        9.3.2. Government / Public

        9.3.3. Non-governmental Organizations

        9.3.4. Others

10. Global Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029, By Area 

    10.1. Introduction / Key Findings

    10.2. Historical Number of Trials and Expenditure (US$ Mn) By Area, 2014-2018

    10.3. Current and Future Number of Trials and Expenditure (US$ Mn) and Forecast By Area, 2019 - 2029

        10.3.1. Oncology

        10.3.2. Infectious Disease

        10.3.3. Metabolic Disorders

        10.3.4. Cardiovascular

        10.3.5. Neuroscience

        10.3.6. Respiratory

        10.3.7. Others 

11. Global Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029, By Stage

    11.1. Introduction / Key Findings

    11.2. Historical Number of Trials and Expenditure (US$ Mn) By Stage, 2014-2018

    11.3. Current and Future Number of Trials and Expenditure (US$ Mn) and Forecast By Stage, 2019 - 2029

        11.3.1. Phase 0

        11.3.2. Phase I

        11.3.3. Phase II

        11.3.4. Phase III

        11.3.5. Phase IV

12. Global Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029, By Region

    12.1. Introduction

    12.2. Historical Number of Trials and Expenditure (US$ Mn) By Region, 2014-2018

    12.3. Current Number of Trials and Expenditure (US$ Mn) and Forecast By Region, 2019 - 2029

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. East Asia

        12.3.5. South Asia

        12.3.6. Oceania

        12.3.7. Middle East and Africa (MEA)

13. North America Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029

    13.1. Introduction

    13.2. Regulatory Scenario

    13.3. Historical Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2014-2018

    13.4. Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2019 - 2029

        13.4.1.  By Country

            13.4.1.1. U.S.

            13.4.1.2. Canada

        13.4.2. By Sponsor

        13.4.3. By Area

        13.4.4. By Stage

    13.5. Market Trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

14. Latin America Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029

    14.1. Introduction

    14.2. Regulatory Scenario

    14.3. Historical Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2014-2018

    14.4. Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2019 - 2029

        14.4.1.  By Country

            14.4.1.1. Brazil

            14.4.1.2. Mexico

            14.4.1.3. Argentina

            14.4.1.4. Rest of Latin America

        14.4.2. By Sponsor

        14.4.3. By Area

        14.4.4. By Stage

    14.5. Market Trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

15. Europe Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029

    15.1. Introduction

    15.2. Regulatory Scenario

    15.3. Historical Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2014-2018

    15.4. Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2019 - 2029

        15.4.1.  By Country

            15.4.1.1. Germany

            15.4.1.2. Italy

            15.4.1.3. France

            15.4.1.4. U.K.

            15.4.1.5. Spain

            15.4.1.6. BENELUX

            15.4.1.7. Russia

            15.4.1.8. Poland

            15.4.1.9. Rest of Europe

        15.4.2. By Sponsor

        15.4.3. By Area

        15.4.4. By Stage

    15.5. Market Trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

16. East Asia Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029

    16.1. Introduction

    16.2. Regulatory Scenario

    16.3. Historical Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2014-2018

    16.4. Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2019 - 2029

        16.4.1.  By Country

            16.4.1.1. China

            16.4.1.2. Japan

            16.4.1.3. South Korea

        16.4.2. By Sponsor

        16.4.3. By Area

        16.4.4. By Stage

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

17. South Asia Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029

    17.1. Introduction

    17.2. Regulatory Scenario

    17.3. Historical Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2014-2018

    17.4. Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2019 - 2029

        17.4.1.  By Country

            17.4.1.1. India

            17.4.1.2. Thailand

            17.4.1.3. Indonesia

            17.4.1.4. Malaysia

            17.4.1.5. Singapore

            17.4.1.6. Rest of South Asia

        17.4.2. By Sponsor

        17.4.3. By Area

        17.4.4. By Stage

    17.5. Market Trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

18. Oceania Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029

    18.1. Introduction

    18.2. Regulatory Scenario

    18.3. Historical Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2014-2018

    18.4. Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2019 - 2029

        18.4.1.  By Country

            18.4.1.1. Australia

            18.4.1.2. New Zealand

        18.4.2. By Sponsor

        18.4.3. By Area

        18.4.4. By Stage

    18.5. Market Trends

    18.6. Key Market Participants - Intensity Mapping

    18.7. Drivers and Restraints - Impact Analysis

19. Middle East and Africa Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029

    19.1. Introduction

    19.2. Regulatory Scenario

    19.3. Historical Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2014-2018

    19.4. Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2019 - 2029

        19.4.1.  By Country

            19.4.1.1. GCC Countries

            19.4.1.2. Turkey

            19.4.1.3. South Africa

            19.4.1.4. Rest of Middle East and Africa

        19.4.2. By Sponsor

        19.4.3. By Area

        19.4.4. By Stage

    19.5. Market Trends

    19.6. Key Market Participants - Intensity Mapping

    19.7. Drivers and Restraints - Impact Analysis

20. Emerging Countries Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029

    20.1. Introduction

        20.1.1. Proportion Analysis of Expenditure, By Key Countries

        20.1.2. Growth Comparison of Global Market v/s Emerging Countries

    20.2. China Clinical Trials Landscape Analysis

        20.2.1. Introduction

        20.2.2. Regulatory Scenario

        20.2.3. PEST Analysis

        20.2.4. Proportion Analysis of Expenditure by Market Taxonomy

        20.2.5. Number of Trials and Expenditure (US$ Mn) Forecast by Market Taxonomy

            20.2.5.1. By Sponsor

            20.2.5.2. By Area

            20.2.5.3. By Stage

        20.2.6. China Clinical Trials Landscape – Stakeholder Landscape

    20.3. India Clinical Trials Landscape Analysis

        20.3.1. Introduction

        20.3.2. Regulatory Scenario

        20.3.3. PEST Analysis

        20.3.4. Proportion Analysis of Expenditure by Market Taxonomy

        20.3.5. Number of Trials and Expenditure (US$ Mn) Forecast by Market Taxonomy

            20.3.5.1. By Sponsor

            20.3.5.2. By Area

            20.3.5.3. By Stage

        20.3.6. India Clinical Trials Landscape - Stakeholder Landscape

    20.4. Brazil Clinical Trials Landscape Analysis

        20.4.1. Introduction

        20.4.2. Regulatory Scenario

        20.4.3. PEST Analysis

        20.4.4. Proportion Analysis of Expenditure by Market Taxonomy

        20.4.5. Number of Trials and Expenditure (US$ Mn) Forecast by Market Taxonomy

            20.4.5.1. By Sponsor

            20.4.5.2. By Area

            20.4.5.3. By Stage

        20.4.6. Brazil Clinical Trials Landscape - Stakeholder Landscape

21. Key Stakeholder Assessment

    21.1. Clinical Trials Share Analysis by Top 20 Companies

    21.2. Top 20 Most Valuable R&D Projects, 2018

    21.3. Worldwide Pharmaceutical R&D Spend Projections by Key Companies

    21.4. Landscape of Key Stakeholders in Clinical Trials

        21.4.1. Clinical Research Partners

        21.4.2. Clinical Data Management Providers

22. Assumptions and Acronyms Used

23. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type

Table 02: Global Spending on Clinical Trials  (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type

Table 03: Global Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase

Table 04: Global Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Region

Table 05: North America Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type

Table 06: North America Spending on Clinical Trials  (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type

Table 07: North America Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase

Table 08: North America Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Country

Table 09: Latin America Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type

Table 10: Latin America Spending on Clinical Trials  (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type

Table 11: Latin America Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase

Table 12: Latin America Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Country

Table 13: Europe Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type

Table 14: Europe Spending on Clinical Trials  (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type

Table 15: Europe Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase

Table 16: Europe Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Country

Table 17: East Asia Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type

Table 18: East Asia Spending on Clinical Trials  (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type

Table 19: East Asia Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase

Table 20: East Asia Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Country

Table 21: South Asia Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type

Table 22: South Asia Spending on Clinical Trials  (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type

Table 23: South Asia Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase

Table 24: South Asia Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Country

Table 25: Oceania Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type

Table 26: Oceania Spending on Clinical Trials  (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type

Table 27: Oceania Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase

Table 28: Oceania Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Country

Table 29: MEA Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type

Table 30: MEA Spending on Clinical Trials  (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type

Table 31: MEA Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase

Table 32: MEA Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Country

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018

Figure 02: Global Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029

Figure 03: North America Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018

Figure 04: North America Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029

Figure 05: Latin America Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018

Figure 06: Latin America Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029

Figure 07: Europe Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018

Figure 08: Europe Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029

Figure 09: East Asia Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018

Figure 10: East Asia Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029

Figure 11: South Asia Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018

Figure 12: South Asia Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029

Figure 13: Oceania Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018

Figure 14: Oceania Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029

Figure 15: MEA Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018

Figure 16: MEA Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Pediatric Clinical Trials Market

Published : June 2022

Healthcare

Clinical Mobility Market

Published : June 2016

Healthcare

Clinical Information System Market

Published : March 2022

Google translate

Clinical Trials Market